MedTrace Logo

AC-11 Supplement and Biological Aging

NCT05310123 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2022-04-11

No results posted yet for this study

Summary

This is a prospective non-randomized clinical study of 24 patients to evaluate the effects of the AC-11®. The study will evaluate the effectiveness of the supplement's ability to reverse epigenetic markers of biological age. The duration of the study will be 6 months.

Conditions

  • Aging

Interventions

DIETARY_SUPPLEMENT

AC-11

6-months of treatment with AC-11

Sponsors & Collaborators

  • Optigenex, Inc

    collaborator UNKNOWN

  • TruDiagnostic

    lead INDUSTRY

Principal Investigators

  • Phillip Gallegos · Thrive Medicine Clinic

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-26
Primary Completion
2022-10-31
Completion
2022-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05310123 on ClinicalTrials.gov